Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals

XBI returned 51.2% over the past year versus 32.5% for XPH, but carried materially higher risk, with a 1.12 beta and a 63.9% five-year maximum drawdown compared with XPH's 0.72 beta and 34.9% drawdown. Over five years, XPH produced the stronger total-return outcome, growing $1,000 to $1,327 versus $1,224 for XBI, while both charge a 0.35% expense ratio. The article frames XBI as the higher-growth, more liquid biotech option and XPH as the lower-volatility pharmaceutical alternative for conservative healthcare investors.

Analysis

The relevant distinction is factor exposure, not simply "growth" versus "defense." XBI’s modified equal-weight construction gives it materially greater exposure to small/mid-cap duration, binary clinical readouts, and the biotech financing cycle; it tends to outperform when rates fall, M&A premiums broaden, and IPO/follow-on windows reopen. XPH is also not a megacap-defensive pharmaceutical proxy: its portfolio construction can leave it exposed to smaller commercial-stage drug companies, reimbursement pressure, and generic competition, so its historical drawdown profile should not be extrapolated as a recession hedge.

After a sharp biotech run, the next 1-3 month return is likely driven by whether gains broaden from a handful of liquid diagnostics/vaccine/platform names into the long tail of cash-burning developers. A sustained rally requires falling real yields, positive FDA/clinical cadence, and a higher rate of strategic acquisitions; absent those, XBI’s higher-beta constituents can retrace quickly as capital raises resume. The more consequential 6-18 month catalyst is patent-expiry pressure on large pharma, which supports business-development demand and could create a valuation floor for de-risked biotech assets, but only selectively rather than across the index.

Consensus may be overstating XPH’s diversification benefit because its smaller asset base raises execution and closure-risk considerations during stressed flows, while XBI’s superior liquidity makes it the cleaner vehicle for tactical exposure. There is no standalone directional ETF trade from the comparison alone; the actionable signal is a relative-beta framework tied to macro rates and M&A evidence. Validate holdings and index methodology before implementation, particularly where constituent data appear inconsistent with commonly recognized listed securities.

Key Decisions for Investors

• No immediate outright ETF position solely on this article; set a watch trigger for XBI relative strength versus XPH only if 10-year real yields decline and biotech M&A/financing activity accelerates over the next 4-8 weeks.
• For a risk-on healthcare allocation, express the view as a 3-month long XBI / short XPH pair, sized beta-neutral rather than dollar-neutral; target 10-15% relative upside if the biotech financing/M&A cycle broadens, with a 5-7% relative-stop if real yields rise or XBI breadth deteriorates.
• For defensive healthcare exposure, do not treat XPH as a substitute for large-cap pharma. Use a liquid large-pharma basket or an appropriate broad pharmaceutical proxy instead; reassess XPH only after confirming underlying liquidity, concentration, and constituent accuracy.
• Monitor MRNA, NTRA, and TWST as sentiment/liquidity indicators for XBI. A reversal in these liquid constituents following guidance cuts, clinical disappointments, or secondary offerings would falsify a near-term biotech-beta long before broad ETF performance fully reflects it.